Skip to main content
Zhejiang Huakang Pharmaceutical Co., Ltd. logo

Zhejiang Huakang Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 605077 ISIN · CNE100005477 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 906 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 605077

About Zhejiang Huakang Pharmaceutical Co., Ltd.

https://www.huakangpharma.com/en

Zhejiang Huakang Pharmaceutical Co., Ltd. specializes in the research, development, and large-scale production of functional sugar alcohols. Its core product range includes xylitol, sorbitol, maltitol, erythritol, and xylose. These ingredients are primarily utilized as high-quality sugar substitutes and functional additives within the food, beverage, and personal care sectors. The company employs advanced hydrogenation and separation technologies to ensure high purity and consistency across its product lines. Huakang serves a global market, providing essential raw materials for the formulation of sugar-free and low-calorie consumer goods. The organization maintains a focus on technological innovation and quality management systems to meet international standards for safety and efficacy in ingredient manufacturing.

Recent filings

Filing Released Lang Actions
股票交易异常波动公告
Regulatory Filings Classification · 90% confidence The document is an announcement regarding the company’s A‐share stock experiencing abnormal trading fluctuations over three consecutive days, with explanations and risk warnings. It contains no actual financial statements or detailed report content but is a regulatory disclosure under stock exchange rules. This fits the general “Regulatory Filings” category for miscellaneous compliance announcements (RNS).
2026-06-04 Chinese
中证鹏元关于关注浙江华康药业股份有限公司控股股东、实际控制人变更的公告
Regulatory Filings Classification · 72% confidence The document is an announcement from a credit rating agency (中证鹏元资信评估股份有限公司) regarding the rating of Zhejiang Huakang Pharmaceutical Co., Ltd., specifically addressing changes in its controlling shareholders and actual controllers, and confirming the rating outcome. It is not a corporate financial report, earnings release, management discussion, or statutory filing by the company itself, but rather a third‐party announcement. There is no presentation of full financial statements or detailed investor materials, nor any proxy or AGM voting content. As such it best fits the fallback category for miscellaneous regulatory announcements.
2026-05-29 Chinese
华康股份关于签署一致行动协议之补充协议暨控股股东、实际控制人变更及权益变动的提示性公告
Major Shareholding Notification Classification · 90% confidence The document is a formal announcement (“提示性公告”) detailing a change in the controlling shareholders and actual controller via a supplemental acting‐in‐concert agreement. It provides before and after shareholding tables, shows that the acting‐in‐concert group’s combined stake moved from 32.01% down to 27.67%, and informs shareholders of the new control structure. This is not an earnings release, management report, or capital issue; rather it is a notification of a significant change in share ownership and control. Therefore it best fits Major Shareholding Notification (MRQ).
2026-05-22 Chinese
简式权益变动报告书（余建明）
Major Shareholding Notification Classification · 82% confidence The document is a formal “Simplified Report on Changes of Equity” filed by a significant shareholder (information disclosure obligor) under Chinese securities regulations. It details changes in acting-in-concert relationships and shareholding percentages, which is a classic major shareholding notification. This matches the category for notifying changes in significant share ownership levels (MRQ).
2026-05-22 Chinese
华康股份关于董事会完成换届选举及聘任高级管理人员和审计部经理、证券事务代表的公告
Board/Management Information Classification · 95% confidence The document is an official announcement by Zhejiang Huakang Pharmaceutical Co., Ltd. regarding the completion of the board of directors’ re-election and the appointment of senior management, audit department manager, and securities affairs representative. It provides details on new board composition, committee memberships, and senior management appointments. This clearly falls under Board/Management Information.
2026-05-15 Chinese
华康股份关于公司选举职工代表董事的公告
Board/Management Information Classification · 95% confidence The document is an official announcement by Zhejiang Huakang Pharmaceutical Co., Ltd. regarding the election of an employee representative as a member of the Board of Directors, including details of the incumbent, term, and compliance with relevant laws. This constitutes a change in the company’s board composition, fitting the category for Board/Management Information.
2026-05-15 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.